通心络胶囊佐治后循环缺血性眩晕和预防复发的疗效观察

摘要

Objective To observe the effect of Tongxinluo capsule in the treatment of posterior circulation ischemic vertigo(PCIV) clinical efficacy and safety, as well as its prevention effect. Methods 126 cases of PCIV were randomly divided into two groups, besides the routine intravenous drip of gastrodin injection, the treatment group and the control group were given Tongxinluo capsule and the betahistine mesilate tablets, treatment course was 15 days, clinical efficacy and TCD, ECG index, as well as the side effects of drugs, blood pressure, liver function, renal function were compared in two groups before and after treatment,90 discharged patients were randomly divided into three groups (30 cases in each group) , respectively administrated low-dose Tongxinluo capsule in Tongxinluo prevention group, betahistine mesilate tablets in control group and blank control group, then observe the recurrent of vertigo in three years. Results The curative rate and total effective rate was higher in treatment group than the control group( P < 0. 05, P <0.01). The improvement of the vertebrobasilar mean flow speed, reduce vascular resistance index and EKGST segment changes in treatment group were significantly superior to control group ( P <0.05 ). The two groups had no significant difference in adverse reaction ( P >0.05) , after treatment the blood pressure, and renal function has no obvious change. In a follow-up of 3 years, the vertigo recurrence rates in Tongxinluo prevention group was lower than betahistine mesilate control group and blank control group( P <0.05, P <0.01). Conclusion The effect of Tongxinluo capsule in the treatment and prevention of recurrent vertigo is better than betahistine mesilate tablets.%目的 观察通心络佐治后循环缺血性眩晕(PCIV)的临床疗效和对眩晕复发的预防作用.方法 将126例PCIV患者随机分为2组,在常规治疗基础上,治疗组和对照组分别口服通心络和甲磺酸倍他司汀治疗,疗程均为15 d,比较2组临床疗效和治疗前后经颅多普勒超声指标,以及药物不良反应、血压、肝功能、肾功能情况.在出院的患者中选择90例随机分为3组(各30例),分别给予小剂量通心络、敏使朗预防治疗以及无药物治疗,观察3年内眩晕的复发情况.结果 治疗组痊愈率、总有效率明显高于对照组(P ＜0.05,P＜0.01).治疗组在改善椎—基动脉的平均血流速度、降低动脉指数和血管阻力指数、频谱图改善等方面明显优于对照组(P均＜0.05).不良反应2组比较差异无统计学意义(P＞0.05),且治疗后血压、肝肾功能无变化.在随访观察的3年中,眩晕复发率通心络预防治疗组＜对照组＜空白对照组(P＜0.05,P＜0.01).结论 通心络在佐治PCIV和预防眩晕复发方面均有良好效果.